Chronic treatment of hemizygous JNPL3 mice carrying the gene for human tau-P301L mutant with Thiamet-G, an OGA inhibitor, leads to a significant reduction of NFTs without altering global tau phosphorylation levels at AD-relevant sites (AT8 and pS422) while O-GlcNAc levels were increased significantly, only AT8 immunoreactivity of tangles was reduced (31). This evidence concerns the gene MAPT and Alzheimer disease.